AVTX

Avalo Therapeutics, Inc.

13.00 USD
+0.54 (+4.33%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avalo Therapeutics, Inc. stock is down -0.31% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 July’s closed higher than June.

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease and systemic juvenile idiopathic arthritis.